renaldofyans89

Male
Social Links
Bio
Deca Durabolin: Uses, Benefits, And Side Effects

ICI 182 780 (Fulvestrant, brand name ICI‑182 780, also marketed as Faslodex)

> Drug class: Selective estrogen receptor degrader (SERD)

> Formulation: Intramuscular (IM) injection, 250 mg in 0.5 mL or 500 mg in 1 mL (commercially available in 250‑ and 500‑mg prefilled syringes).

> Approved indications (US):

> • 1st‑line endocrine therapy for postmenopausal women with hormone‑receptor positive, HER2‑negative metastatic breast cancer.

> • 2nd‑line therapy after progression on aromatase inhibitors or other endocrine agents (except when contraindicated).

---

1. Mechanism of Action

Step Detail

a) Binding Fulvestrant is a pure anti‑estrogen that binds competitively to the ligand‑binding domain of estrogen receptor alpha (ERα) with high affinity, but unlike tamoxifen it has no agonist activity.

b) Receptor degradation The drug induces a conformational change that promotes ubiquitination and proteasomal degradation of ERα, leading to a marked decrease in total ER protein levels (up to 70‑90 % reduction).

c) Transcriptional inhibition Loss of ER reduces transcription of estrogen‑responsive genes such as pS2, cyclin D1, and c‑Myc; this results in cell cycle arrest at G0/G1.

d) Apoptosis induction Prolonged ER suppression increases pro‑apoptotic factors (Bax/Bcl‑2 ratio), decreases anti‑apoptotic MCL‑1, and triggers intrinsic apoptosis pathways.

e) Clinical outcomes In metastatic breast cancer, phase III trials show progression‑free survival improvement of ~3–4 months versus control; objective response rates 15–25 %. The drug is most effective in ER‑positive/HER2‑negative disease and shows synergy with CDK4/6 inhibitors.

---

Summary of Key Differences

Feature Inhibitor (Targeting a Specific Protein) Inhibitor (Blocking an Entire Pathway)

Specificity Very high for the chosen protein; off‑target effects limited to proteins with similar motifs. Lower specificity; may affect multiple proteins within the pathway.

Side‑Effect Profile Usually fewer systemic side effects if the target is not widely expressed. Higher risk of broad toxicity (e.g., cardiotoxicity, neurotoxicity).

Resistance Mechanisms Often involve mutations in the binding site or upregulation of compensatory pathways. Resistance may arise from pathway bypass, alternative signaling loops, or secondary mutations.

Therapeutic Window Can be narrow if target is essential for normal cells; requires precise dosing. Wider window may be possible due to redundant mechanisms but can still cause off‑target effects.

---

4. Practical Tips for Designing a Highly Specific Small‑Molecule Inhibitor

Step What to Do Why It Matters

Target Identification Use proteomics, phosphoproteomics, or CRISPR screens to confirm that the kinase is truly essential in the disease context. Reduces risk of hitting a non‑essential protein that would lead to toxicity or resistance.

Selectivity Profiling Early Run a kinase panel (e.g., DiscoverX KINOMEscan) with >200 kinases at 1–10 µM. Aim for ≥90 % selectivity at the highest tested concentration. Identifies off‑targets early; saves time and cost on later ADMET testing.

Fragment‑Based Lead Discovery Screen fragments (MW 150–300) by NMR or X-ray. Use a protein‐binding assay to confirm hits. Fragments are highly efficient, often bind covalently at unique positions, reducing off‑target risk.

Structure‑Based Optimization Use crystal structures of the fragment bound to the kinase. Identify unique pocket residues (e.g., gatekeeper hinge). Optimize interactions with these residues; avoid common motifs like ATP‑binding hinge hydrogen bonds that may cause promiscuity. Enhances potency while maintaining selectivity.

Iterative SAR Studies For each series, synthesize analogs varying substituents at key positions (R1, R2, etc.). Measure binding affinity and IC50 against the target kinase and a panel of related kinases. Use computational docking to predict off‑target interactions; discard structures predicted to bind common pockets in other kinases. Fine-tunes selectivity profile.

Cellular Assays Test compounds in cellular models expressing the target kinase. Verify that activity correlates with biochemical potency and is not due to general cytotoxicity. Confirms functional relevance.

ADMET Profiling Evaluate metabolic stability, plasma protein binding, permeability, and potential toxicity early. Prioritize molecules with favorable ADMET properties. Reduces risk of late‑stage failures.

---

4. Practical Tips for a Successful Hit‑to‑Lead Process

Tip Explanation

Start with a well‑characterized assay A robust, reproducible biochemical or cellular assay reduces false positives and streamlines the selection of true hits.

Use orthogonal validation Confirm activity using a different readout (e.g., fluorescence vs. luminescence) to eliminate assay artefacts.

Perform early structural analysis If X‑ray co‑crystal structures or cryo‑EM data are available, analyze binding modes before extensive synthesis.

Employ computational docking sparingly Docking can guide SAR but should not replace experimental data; validate predictions with real assays.

Iterate quickly between chemistry and biology Short cycles of design → synthesis → testing accelerate convergence toward a potent lead compound.

Keep an eye on ADMET from the start Even modest improvements in potency are wasted if the molecule cannot be delivered orally or is toxic.

---

7. Practical Workflow Example (Hypothetical)

Week 0–2: Data Gathering

- Download PDB structure, identify binding pocket.
- Extract known inhibitors from ChEMBL/BindingDB; note IC₅₀ values.

Week 3–4: Lead Identification

- Dock top 10 ligands → rank by predicted affinity.
- Choose the best binder (e.g., a benzamide derivative).

Week 5–6: In‑silico Optimization

- Perform MM‑GBSA on bound complex → refine interactions.
- Propose three analogues with altered substituents.

Week 7–8: ADMET Screening

- Run pkCSM predictions for each analogue → discard those violating Lipinski, high CYP inhibition.

Week 9–10: Final Selection & Synthesis Planning

- Pick two analogues with best predicted activity and drug‑likeness.
- Outline synthetic route (e.g., acylation of aniline, Suzuki coupling).

Week 11 Onward: Experimental Validation

- Execute synthesis, purify products.
- Test in vitro potency against target enzyme or cell line.

---

Summary

Day‑to‑day workflow: literature mining → data extraction → database creation → property prediction → hit prioritization → synthetic planning → compound generation → experimental testing.

Key decision points: selection of descriptors, threshold for activity, choice of synthetic route, and whether to pursue further analogues.

Time allocation: 1–2 weeks for initial data gathering; ongoing iterative cycles thereafter.

By following this structured approach, you can efficiently transition from raw literature to a focused set of chemical compounds ready for experimental validation.
https://ozzojobs.com/employer/183734/sermorelin-vs-cjc-1295-advantages-and-disadvantages

Weekly Top Tracks

Browse Music

Your Music

renaldofyans89

Artists to Follow

Weekly Top Tracks

Telman - ON A LOW

Okal - Know

Udo ga achi

Normal Thing

Trez M-COMMOTION

COLD

Steevane - Wait for Me

Majeh- Casket Love

Vherse - Aye

Rayona-TESTIMONY

Queue